
ASCO: Roche details Itovebi's survival benefit in certain breast cancers, further backing blockbuster plan
Roche, hoping to carve out a standard-of-care spot for its PI3K inhibitor Itovebi, now has another leg to stand on with new evidence that shows the drug can extend the lives of certain patients with breast cancer. Adding Itovebi to Ibrance and Faslodex …